Mayo Clinic Laboratory and pathology research roundup: June 7

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Nuclear GSK-3β and oncogenic KRas lead to the retention of pancreatic ductal progenitor cells phenotypically similar to those seen in IPMN.

Glycogen synthase kinase-3β (GSK-3β) is a downstream target of oncogenic KRas and can accumulate in the nucleus in pancreatic ductal adenocarcinoma (PDA). To determine the interplay between oncogenic KRas and nuclear GSK-3β in PDA development, we generated Lox-STOP-Lox (LSL) nuclear-targeted GSK-3β animals and crossed them with LSL-KRasG12D mice under the control of the Pdx1-cre transgene-referred to as KNGC. Altogether, these data identify nGSK-3β and KRasG12D as an important signaling node promoting the retention of pancreatic ductal progenitor cells.

Read more.

Published to PubMed This Week

Meghann Southwick

Meghann Southwick is a marketing specialist for Mayo Clinic Laboratories. She has worked at Mayo Clinic since 2021.